Incretin-based therapy for type 2 diabetes: A real class effect?

International Journal of Cardiology

Volumn 227, Issue , 2017, Pages 141-142

  Savarese, Gianluigi ^a   Lund, Lars H ^a   Rosano, Giuseppe M C ^b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; PLACEBO; SAXAGLIPTIN; ANTIDIABETIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; HEART FAILURE; HOSPITALIZATION; HUMAN; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; META ANALYSIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84995595413     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.11.018     Document Type: Article

References (15)

1. [1] Grundy, S.M., Benjamin, I.J., Burke, G.L., et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100 (1999), 1134–1146.
2. [2] Pareek, M., Aharaz, A., Nielsen, M.L., et al. Untreated diabetes mellitus, but not impaired fasting glucose, is associated with increased left ventricular mass and concentric hypertrophy in an elderly, healthy, Swedish population. IJC Metab. Endocrine 9 (2015), 39–47.
3. [3] Quintana, H.K., Janszky, I., Gigante, B., et al. Diabetes, hypertension, overweight and hyperlipidemia and 7-day case-fatality in first myocardial infarction. IJC Metab. Endocrine 12 (2016), 30–35.
4. [4] Fitchett, D.H., Udell, J.A., Inzucchi, S.E., Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur. J. Heart Fail., 2016, 10.1002/ejhf.633.
5. [5] Rosano, G.M., Clinical trial design, endpoints, and regulatory requirements. Handb. Exp. Pharmacol., 2016 (Epub ahead of print).
6. [6] Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369 (2013), 1317–1326.
7. [7] Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373 (2015), 232–242.
8. [8] White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369 (2013), 1327–1335.
9. [9] Fadini, G.P., Avogaro, A., Degli Esposti, L., Russo, P., Saragoni, S., Buda, S., Rosano, G., Pecorelli, S., Pani, L., Network, O.M.H.-D.B., Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur. Heart J. 36 (2015), 2454–2462.
10. [10] Vitale, C., Rosano, G.M., Prasad, K., Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes. Cardiovasc. Diabetol., 15, 2016, 55.
11. [11] Cheng, X.W., Murohara, T., Kuzuya, M., GLP-1R agonists for the prevention of cardiac injury in STEMI patients undergoing PCI: something new and promising, or not?. IJC Metab. Endocrine 1 (2016), 1–3.
12. [12] Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373 (2015), 2247–2257.
13. [13] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375 (2016), 311–322.
14. [14] Savarese, G., Perrone-Filardi, P., D'Amore, C., et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis. Int. J. Cardiol. 181 (2015), 239–344.
15. [15] Savarese, G., D'Amore, C., Federici, M., et al. Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis. Int. J. Cardiol. 220 (2016), 595–601.